BRIEF-Immunomedics achieves patient enrollment for single-arm Phase 2 study with sacituzumab govitecan

* Immunomedics announces achievement of patient enrollment

into single-arm phase 2 study with sacituzumab govitecan

(immu-132) in triple-negative breast cancer

Read more